KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Petrylak, D. P. [1 ]
Li, B. [2 ]
Schloss, C. [2 ]
Fizazi, K. [3 ]
机构：
[1] Yale Univ, Smilow Canc Hosp, Med Oncol, New Haven, CT USA
[2] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[3] Gustave Roussy, Canc Med, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
891TiP
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
    Yu, E. Y.
    Park, S. H.
    Goh, J. C. H.
    Shin, S. J.
    Mehra, N.
    McDermott, R.
    Sala Gonzalez, M. A.
    Fong, P. C.
    Greil, R.
    Retz, M.
    Sade, J. P.
    Huang, Y-H.
    Begbie, S.
    Rey, F.
    Kramer, G.
    Suzuki, H.
    Zhang, J.
    Kim, J.
    Poehlein, C. H.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1163 - S1164
  • [32] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
    Augustin, Marinela
    Laguerre, Brigitte
    Baldini, Capucine
    Zedan, Ahmed H.
    Gonzalez-Billalabeitia, Enrique
    Fong, Peter C. C.
    Zukov, Ruslan
    Hammerer, Peter
    Prentice, Mark
    Shore, Neal D.
    Necchi, Andrea
    Todenhoefer, Tilman
    Kessler, Elizabeth R.
    Kose, Fatih
    Gurney, Howard
    Valderrama, Begona Perez
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
  • [33] Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration -resistant prostate cancer (mCRPC).
    Parimi, Sunil
    Eigl, Bernhard J.
    Sunderland, Katherine
    Zulficiar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Seto, Leanne Chung-Yon
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] KEYNOTE-641: Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer
    Graff, Julie N.
    Liang, Li Wen
    Kim, Jeri
    Stenzl, Arnulf
    FUTURE ONCOLOGY, 2021, 17 (23) : 3017 - 3026
  • [35] KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Goh, Jeffrey C. H.
    Ojamaa, Kristiina
    Rodriguez, Jose Maria Piulats
    Drake, Charles G.
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
    Mehra, Niven
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    McDermott, Raymond S.
    Gonzalez, Nuria Sala
    Fong, Peter C. C.
    Greil, Richard
    De Santis, Maria
    Yanez, Patricio Eduardo
    Huang, Yi-Hsiu
    Begbie, Stephen
    Rey, Felipe
    Kramer, Gero
    Suzuki, Hiroyoshi
    Saretsky, Todd L.
    Ghate, Sameer R.
    Cui, Yi
    Kim, Jeri
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] A randomized phase II cross-over study of abiraterone plus prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration resistant prostate cancer (mCRPC).
    Chi, Kim N.
    Annala, Matti
    Sunderland, Katherine
    Khalaf, Daniel
    Finch, Daygen
    Oja, Conrad D.
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Beja, Kevin
    Vandekerkhove, Gillian
    Gleave, Martin
    Wyatt, Alexander William
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [40] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345